 | |
 | |
| Clinical data | |
|---|---|
| Other names | CX-691; ORG-24448 |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H13N3O2 |
| Molar mass | 231.255 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Farampator (developmental code namesCX-691,ORG-24448,SCH-900460) is anampakine drug. It was developed byCortex Pharmaceuticals, and licensed toOrganon BioSciences for commercial development. Following the purchase of Organon bySchering-Plough in 2007, the development license to farampator was transferred. The development of farampator was eventually terminated, reportedly due to concerns aboutcardiac toxicity.[1][2]
Farampator has been investigated for its effect onAMPA receptors and researched for potential use in the treatment of schizophrenia andAlzheimer's disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects such as headache, somnolence and nausea. Subjects reporting side effects had significantly higher plasma levels of farampator than subjects without.[citation needed] Additional analyses revealed that in the farampator condition the group without side effects showed a significantly superior memory performance relative to the group with side effects.[3]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
